Metformina Aurovitas

Metformin, the active ingredient in Metformina Aurovitas, is a Biguanide presented as an oral dosage form for oral use. It is used to lower elevated blood glucose levels in adults with type 2 diabetes mellitus. GNH USA supplies Metformina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Aurovitas, a biguanide antidiabetic, is employed in the management of glucose metabolism disorders. - Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity.

Metformina Aurovitas may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea. - Metallic taste: transient alteration of taste perception. - Vitamin B12 deficiency: reduced absorption with long‑term use. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe hypoglycaemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Skin reactions: rash or urticaria.

Metformina Aurovitas requires careful patient assessment and monitoring. - Renal function: evaluate eGFR before initiation and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor for signs of heart failure. - Alcohol consumption: advise limiting intake to reduce lactic acidosis risk. - Pregnancy and lactation: assess risk‑benefit ratio before prescribing. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Metformina Aurovitas can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging. - Alcohol: increases risk of lactic acidosis. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia; adjust dose as needed. - Diuretics (especially thiazides): may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, requiring closer monitoring.